Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
PGA Frac Ball
Contact UsPGA fully degradable frac plug ball is a series of frac plug balls developed based on PGA degradable materials to meet the needs of oil fields under various temperatures and working conditions.
-
Black Currant Juice Powder
Contact UsLatin Name: Ribes nigrum L.
Synonyms:
Part of Used: Fruit
Specifications: Freeze-dried, 80mesh; Freeze-dried, 80mesh
Appearance:
Application: Food Supplements,Nutritional Supplement, Functional Food, Beverages/Solid Beverage -
7000A 12V&24V Jump Starter for Truck Starting in -40C
Contact Us（*For Jump Starter ODM/OEM Solutions, secure your exclusive quotation now!）
-
Titanium Alloy Coil
Contact UsWe adhere to the business philosophy of “gathering all the steel in the world and achieving stainless quality”, sincerely looking forward to the joining and cooperation of domestic and foreign merchants, new and old users, and working together to create brilliance
Reviews
There are no reviews yet.